BMJ3d
FRI0293 Validation of the revised selena flare index in systemic lupus erythematosus
Background The SELENA flare index (SFI) has functioned well in clinical and clinical trial settings (1), but has the limitation that it classifies only severe versus combined mild/moderate flares.
BMJ12d
Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis
Objectives Various hypotheses exist for the explanation of placebo response rates in randomised controlled trials (RCTs) of patients with rheumatoid arthritis with IR to methotrexate (MTX). We ...
BMJ1d
POS0068 FLARE AND DRUG-FREE REMISSION IN RHEUMATOID ARTHRITIS - CLINICAL PREDICTORS FROM THE BIO-FLARE STUDY
Background: Rheumatoid arthritis (RA) flares remain poorly understood at a mechanistic level and have been difficult to study because of their sporadic nature. BIO-FLARE (BIOlogical Factors that Limit ...
BMJ11d
Medications associated with fracture risk in patients with rheumatoid arthritis
Objective To examine the fracture risk with use of disease-modifying antirheumatic drugs (DMARDs), statins, proton pump inhibitors (PPIs), opioids, non-opioid analgesics and psychotropic medications ...
BMJ11d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
BMJ11d
Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series
Correspondence to Dr Peter Kvacskay, Department of Internal Medicine V Hematology Oncology Rheumatology, University Hospital Heidelberg, Heidelberg 69120, Germany; peter.kvacskay{at}med.uni-heidelberg ...
BMJ8d
Oral steroid in the treatment of carpal tunnel syndrome
Dr S M Wong, Department of Medicine, Prince of Wales Hospital, 30–32 Ngan Shing Street, Shatin, New Territories, Hong Kong, Special Administrative Region China A range of options are available for the ...
BMJ6d
How the type of risk reduction influences required sample sizes in randomised clinical trials
Department of Internal Medicine, Division of Rheumatology, University of Maastricht, Maastricht, The Netherlands Correspondence to: Professor D van der Heijde Department of Internal Medicine, Division ...
BMJ8d
Gut microbiome in rheumatic diseases
Correspondence to Professor Sergey Moiseev, Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow 119435, Russian Federation; avt420034{at}yahoo.com Gut microbiome ...
BMJ6d
When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
Objective: To evaluate the efficacy and safety of adding sulfasalazine to leflunomide treatment compared with switching to sulfasalazine alone in patients with RA with an inadequate response to ...
BMJ12d
Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis
Correspondence to Professor Daniel Aletaha, Department of Medicine III, Medical University of Vienna, Wien 1090, Austria; daniel.aletaha{at}meduniwien.ac.at Objectives To investigate whether treatment ...
BMJ3d
AB1717-PARE DERMATOMYOSITIS BURDEN OF DISEASE MANIFESTATIONS AND QOL IMPACT: PATIENT-REPORTED SURVEY RESULTS
Background Dermatomyositis (DM) is a rare, multi-system idiopathic inflammatory myopathy characterized by skin rash and muscle weakness that is often accompanied by pain and fatigue. Other ...